Hoth Therapeutics Stock Surges After Signing Production Agreement

Biopharmaceutical firm Hoth Therapeutics (NASDAQ: HOTH) shares are rallying on new years eve after the company said it has signed a production agreement for GLP and GMP materials associated with HT-001 with Tergus Pharma for its novel cancer treatment drug, HT-001.

Hoth Therapeutics shares rose to highs of $3.09 on the news. Since the opening bell, its shares have given up some of those gains and are currently trading at $2.55, +55.49%.

Today’s announcement follows recent news that the company has requested a pre-investigational new drug meeting with the FDA to discuss a proposed drug development program for the treatment.

WELCOME BONUS - Free Share Bundle When You Invest £50! Get up to £500 cashback for investing with IG.

Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.

5.0

Open Account Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

HT-001 is designed to treat patients with a mild to moderate rash and skin disorders associated with initial and repeat courses of tyrosine kinase inhibitor/epidermal growth factor receptor (EGFR) inhibitor therapy.

EFGR inhibitors are used to treat cancers with HT-001 targeted to treat these EGFR-induced skin disorders and allow patients to achieve the best potential outcomes of EGFR therapy.

“Hoth management is pleased with the advancement of our HT-001 treatment throughout the developmental process,” commented Robb Knie, Hoth’s CEO.